The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) 4

Overview

About this study

This study will develop a complete dataset of outcomes on the largest prospectively and rigorously phenotyped ADPKD cohort with ~20 years of follow-up and accompanying biospecimen repository, which will be a valuable and unique resource for biomarker discovery, validation, and model building for the current proposal and for the greater PKD scientific community.

This study proposes to continue follow-up of the CRISP observational cohort of patients with autosomal dominant polycystic kidney disease (ADPKD), and to follow-up patients from the HALT Study A. Since the goal of this study is to elucidate the natural history of ADPKD in patients, this can only be achieved through the study of human subjects.

Through this study, knowledge will be gained about the natural history of the disease, biomarkers that can predict the subsequent course of the disease, and models to predict the risk and timing of development of kidney failure.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Subjects will be recruited from the cohort of subjects currently followed at each PCC for CRISP III and from the list of patients that were active in HALT Study A at the time the study was closed in 2014.

All patients that were enrolled into CRISP originally in 2001 that are alive and have not yet reached ESRD will be eligible for inclusion in CRISP IV. All patients in HALT Study A that were followed at any of the original CRISP sites (i.e. Kansas, Mayo and Emory) that are alive and have not yet reached ESRD will be eligible for inclusion in the HALT extension cohort.

Subjects will be selected for inclusion without regard to sex/gender, race or ethnicity, but will be limited to those patients that originally participated in CRISP or HALT Study A at Kansas, Emory or Mayo and have not yet died or reached end-stage renal disease.

Children as young as 15 years old were included in the original CRISP (enrollment 2001-2002) and HALT Study A (enrollment 2006-2009) cohorts. Because this proposal is to follow-up these pre-enrolled cohorts as they age, the subjects by necessity will be older, with an expected age range of 23-63 years (mean ~47 years).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Vicente Torres, M.D., Ph.D.	Closed for enrollment	Contact information: Elizabeth Manggaard CCRP (507) 266-4616 Bungum.Lisa2@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Vicente Torres, M.D., Ph.D.

Closed for enrollment

Contact information:

Elizabeth Manggaard CCRP

(507) 266-4616

Bungum.Lisa2@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials